Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21165040 | 0.90 | — | — | |
| SCHEMBL24308601 | 0.87 | — | — | |
| SCHEMBL20939371 | 0.87 | CHRM2 (0.47) | ALDH1A1L3MBTL1CHRM2 | |
| SCHEMBL23206533 | 0.87 | — | — | |
| SCHEMBL19992145 | 0.87 | CHRM2 (0.47) | ALDH1A1L3MBTL1CHRM2 | |
| SCHEMBL24308844 | 0.87 | — | — | |
| SCHEMBL20384083 | 0.83 | — | — | |
| SCHEMBL2274269 | 0.79 | CHRM2 (0.45) | ALDH1A1L3MBTL1CHRM2 | |
| SCHEMBL15918974 | 0.79 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1CHRM2 | |
| SCHEMBL20384062 | 0.79 | CHRM2 (0.45) | ALDH1A1L3MBTL1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400493-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023240188-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3512858-B1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4242211-A1 | IMIDAZOTHIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Guangzhou Henovcom Bioscience Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-3794061-B1 | PHOSPHORUS CONTAINING OLIGOMERS AND POLYMERS | EMPA EIDGENOESSISCHE MAT & FORSCHUNGSANSTALT (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2022100727-A1 | IMIDAZOTHIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2022-05-19 | — | — | WO | disclosed |
| WO-2021259309-A1 | GLP-1 RECEPTOR AGONIST, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| EP-3805234-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Guangzhou Henovcom Bioscience Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceultica nv (BE) | 2019-07-18 | — | — | US | disclosed |
| EP-3174879-B1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2018-07-18 | — | — | EP | disclosed |
| WO-2018050684-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-22 | — | — | WO | disclosed |
| US-20170097567-A1 | METHOD FOR PRODUCING POLYMER | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| US-20160229940-A1 | POLYMER, RESIST COMPOSITION, AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20110202328-A1 | System for the determination of selective absorbent molecules through predictive correlations | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110202328-A1 | System for the determination of selective absorbent molecules through predictive correlations | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110202328-A1 | System for the determination of selective absorbent molecules through predictive correlations | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | ALDH1A1 3997/4885L3MBTL1 615/4885CHRM2 4569/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ALDH1A1 4542/4885L3MBTL1 4663/4885CHRM2 120/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | ALDH1A1 1358/4885L3MBTL1 815/4885CHRM2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.